Abstract
India’s contract research organizations (CROs) are no longer just low-cost compound synthesizers. Over the past 15 years, they have asserted themselves as world-class chemistry-service providers. Now, the country’s top CROs are setting up labs in the West, fostering global teams, and courting biotechnology companies. The goal of their executives is nothing less than becoming integrated partners for global drugmakers and going head to head with China as the world’s powerhouse drug discovery partner. Amid the economic turbulence and supply chain upsets of the past 2 years, big pharmaceutical companies have been quietly moving some of their drug discovery projects from research outsourcing partners in China to partners in India. The diversification effort started before the pandemic, says Ramesh Subramanian, chief commercial officer at Aragen Life Sciences, one of India’s leading contract research organizations (CROs). “What we’re seeing is a significant focus from companies on diversifying their geographical footprint,” he says.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
